



# Cell Therapy Innovation 360°

*From basic research to patient delivery*

## PROGRAMME

WEDNESDAY 19<sup>TH</sup>  
AND  
THURSDAY 20<sup>TH</sup> JANUARY 2022

3<sup>RD</sup> EDITION

[www.cti360congress.com](http://www.cti360congress.com)



**OLIMPE**  
CRÉATEUR DE VALEUR EN IMMUNOLOGIE

 LA REVUE  
Immunité & Cancer

*Mieux comprendre pour mieux traiter*

# Wednesday 19<sup>th</sup> January 2022

10<sup>30</sup> - 10<sup>40</sup>

## WELCOME & INTRODUCTION

*Gilles Salles (New York, USA)*  
*Jean-Yves Blay (Lyon, France)*

10<sup>40</sup> - 11<sup>10</sup>

## KEYNOTE LECTURE

### CAR T-CELL DELIVERY: EXPLORING NEW METHODS

*Moderator: Gilles Salles (New York, USA)*  
*Speaker: Crystal Mackall (Stanford, USA)*

11<sup>10</sup> - 12<sup>25</sup>

### CAR T-CELLS IN LYMPHOMA, MYELOMA & ALL: LATEST CLINICAL DATA

*Moderator: Susana Rives (Barcelona, Spain)*  
*Speakers: Ulrich Jäger (Vienna, Austria)*  
*Nikhil Munshi (Boston, USA)*  
*André Baruchel (Paris, France)*

12<sup>25</sup> - 13<sup>25</sup>

## LUNCH BREAK

13<sup>25</sup> - 14<sup>25</sup>

## INDUSTRY SATELLITE SYMPOSIUM



14<sup>25</sup> - 15<sup>10</sup>

### OPTIMAL TREATMENT SEQUENCING: THE PLACE OF HSCT, BITES & CAR T-CELLS IN DLBCL & MYELOMA

*Moderator: Jacques-Olivier Bay (Clermont-Ferrand, France)*  
*Speakers: Guillaume Cartron (Montpellier, France)*  
*Philippe Moreau (Nantes, France)*

Wednesday 19<sup>th</sup> January 2022

15<sup>10</sup> - 15<sup>55</sup>

## MYELOMA: CLINICAL CASE

Supported by



Moderator: Bertrand Arnulf (Paris, France)

Speakers: Lionel Karlin (Lyon, France)

Philippe Moreau (Nantes, France)

15<sup>55</sup> - 17<sup>05</sup>

## REAL-LIFE EXPERIENCE

### **The DESCART Registry**

Speaker: Roch Houot (Rennes, France)

### **From patient selection to infusion**

Speakers: Catherine Thieblemont (Paris, France)

Susana Rives (Barcelona, Spain)

### **Toxicity management in multiple myeloma**

Speaker: Nikhil Munshi (Boston, USA)

17<sup>05</sup> - 17<sup>25</sup>

**BREAK**

17<sup>25</sup> - 18<sup>25</sup>

**INDUSTRY SATELLITE SYMPOSIUM**

Celgene |  Bristol Myers Squibb<sup>™</sup>  
Company

18<sup>25</sup> - 18<sup>55</sup>

## **CAR T-CELLS: WHAT HAS BECOME OF LONG-TERM SURVIVORS?**

Moderator: André Baruchel (Paris, France)

18<sup>55</sup>

**CONCLUSION**

Thursday 20<sup>th</sup> January 2022

09<sup>00</sup> - 09<sup>30</sup>

## HOW CAN CAR-T EFFICACY BE IMPROVED?

Moderator: Emmanuel Bachy (Lyon, France)  
Speaker: Stanley Riddell (Seattle, USA)

09<sup>30</sup> - 10<sup>30</sup>

## INDUSTRY SATELLITE SYMPOSIUM

Celgene |  Bristol Myers Squibb<sup>™</sup>  
Company

10<sup>30</sup> - 10<sup>50</sup>

## BREAK

10<sup>50</sup> - 11<sup>10</sup>

## HOW DO ENGINEERED T-CELLS KILL THEIR TARGET?

Moderator: Roch Houot (Rennes, France)  
Speaker: Philippe Bousso (Paris, France)

11<sup>10</sup> - 12<sup>10</sup>

## CELLULAR THERAPIES: WHAT DOES THE FUTURE HOLD?

Speakers: Katy Rezvani (Houston, USA)  
Justin Eyquem (San Francisco, USA)  
Michael Hudecek (Würzburg, Germany)

12<sup>10</sup> - 13<sup>00</sup>

## LUNCH BREAK

13<sup>00</sup> - 13<sup>40</sup>

## BIOTECH PRESENTATIONS





Thursday 20<sup>th</sup> January 2022

INDUSTRY SATELLITE SYMPOSIUM



13<sup>40</sup> - 14<sup>40</sup>

**CAR T-CELLS IN SOLID TUMORS: WHAT IS NEW?**

*Moderator: Antoine Italiano (Bordeaux, France)*

*Speakers: Jean-Yves Blay (Lyon, France)*

*Christopher Klebanoff (New York, USA)*

14<sup>40</sup> - 15<sup>10</sup>

15<sup>10</sup> - 15<sup>50</sup>

**CAR T-CELLS IN HEMATOLOGIC MALIGNANCIES:  
NEW CHALLENGES**

*Speakers: Gilles Salles (New York, USA)*

*André Baruchel (Paris, France)*

15<sup>50</sup> - 16<sup>50</sup>

**REGIONAL ORGANIZATION IN FRANCE:  
MANAGING THE INCREASE IN INDICATIONS FOR  
CAR-T THERAPY**

*Moderator: Corinne Haioun (Créteil, France)*

*Speakers: Emmanuel Bachy (Lyon, France)*

*Krimo Bouabdallah (Bordeaux, France)*

*Nicolas Boissel (Paris, France)*

*Xavier Leleu (Poitiers, France)*

16<sup>50</sup>

**CONCLUSION**



# Cell Therapy Innovation 360°

*From basic research to patient delivery*

## CHAIRMEN

### Prof. Gilles Salles Hematologist

Memorial Sloan Kettering  
Cancer Center  
New York, USA



### Prof. Jean-Yves Blay Oncologist

Université Claude Bernard Lyon 1  
Centre Léon Berard  
Lyon, France



## SCIENTIFIC COMMITTEE

**Prof. Bertrand Arnulf** (Hôpital Saint-Louis, Paris, France)

**Prof. Emmanuel Bachy** (Hospices Civils, Lyon, France)

**Prof. André Baruchel** (Hôpital Robert Debré, Paris, France)

**Prof. Jacques-Olivier Bay** (CHU, Clermont-Ferrand, France)

**Prof. Nicolas Boissel** (Hôpital Saint-Louis, Paris, France)

**Prof. Guillaume Cartron** (CHU, Montpellier, France)

**Prof. Roch Houot** (CHU, Rennes, France)

**Prof. Ulrich Jäger** (Medical University, Vienna, Austria)

**Prof. Véronique Minard** (Gustave Roussy, Villejuif, France)

**Dr. Susana Rives** (Hospital Sant Joan de Déu Barcelona,  
Esplugues de Llobregat, Spain)